Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Intellia Therapeutics Announces More Good News

April 5, 2021 0

Intellia Therapeutics NTLA-2001 for ATTR Granted Orphan Drug Designation by the EC Intellia Therapeutics (NTLA) announced …

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

April 1, 2021 0

Exelixis Boxed in on Good News Exelixis (EXEL) is one of the firms boxed in by …

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN’s Stock Price

March 31, 2021 0

Illumina Acquisition of GRAIL On September 21, 2020, Illumina and GRAIL Inc. announced that they entered into …

A Biotech Firm We Love to Discover

March 30, 2021 0

Rubius Therapeutics Finding small development-stage biotech firms that contribute to biotechnology's limitless revolution of the biological …

Your Questions, Our Answers

March 28, 2021 2

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues …

Intellia Therapeutics’ Important Current Presentations

March 25, 2021 0

Current Presentations from Intellia Therapeutics Intellia Therapeutics (NTLA) is presenting the first preclinical data set on …

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

March 24, 2021 0

Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC Novartis (NVS) reported the first interpretable results …

A Flashback and Future Projections

March 24, 2021 0

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from …

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington’s Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

March 23, 2021 0

Negative News from Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced that its partner, Roche (RHHBY),

CureVac Has Very Interesting Future Plans

March 22, 2021 0

CureVac CureVac B.V. (CVAC) is a global biopharmaceutical company specializing in messenger RNA (mRNA) technology. The …

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.

March 17, 2021 0

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19 AstraZeneca (AZN) has modified …

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck’s KEYTRUDA

March 16, 2021 0

Immutep Ltd and Merck Announce Second Clinical Trial Collaboration Immutep (IMMP) develops novel immunotherapy treatments for …

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

March 15, 2021 0

Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences (GILD) and Merck …

Anixa Biosciences: Why This Firm Outperformed Today

March 12, 2021 0

Anixa Biosciences Outperformance Anixa Biosciences Inc (ANIX) is the worldwide licensee of a patent technology titled …

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

March 11, 2021 0

Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology (AVEO) drug FOTIVDA is …

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

March 11, 2021 0

Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology (VIR) and GlaxoSmithKline …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd